Precirix NV, a clinical-stage biotechnology company developing novel radiopharmaceuticals in oncology, and Evergreen Theragnostics, a radiopharmaceutical contract manufacturer, have entered into an agreement whereby Evergreen will provide U.S.-based manufacturing for Precirix’s lead product candidate, CAM-H2.   CAM-H2 is being evaluated in a Phase I/II clinical trial targeting HER2-positive metastatic breast and gastric cancer. The novel precision therapy aims to effectively irradiate canc...